thought leaders

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs are physicians, scientists and academics who devote time to studying and advancing their craft. Often, …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One

Now more than ever, pharmaceutical companies’ relationships with physician thought leaders, also known as key opinion leaders (KOLs), are under intense scrutiny. Industry ethicists and watchdogs alike have speculated on the objectivity of medical education presentations and other aspects of KOL involvement during the marketing of new drug therapies. However, the truth is that physician …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One Read More »